Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 79

of 'Induction therapy for acute myeloid leukemia in younger adults'

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Ritchie DS, McBean M, Westerman DA, Kovalenko S, Seymour JF, Dobrovic A
Blood. 2008;111(5):2896. Epub 2007 Dec 11.
De novo presentation of acute myeloid leukemia (AML) expressing the Philadelphia (Ph) chromosomal abnormality is rare and is associated with a dismal prognosis. To date, reported cases of Ph(+) AML have expressed either the e13a2 or e14a2 BCR-ABL fusion transcripts. We report a unique case of de novo AML expressing the e6a2 fusion transcript and describe disease sensitivity to both imatinib before allogeneic stem-cell transplantation and dasatinib for AML relapse after allogeneic stem-cell transplantation. Furthermore, we report that sustained molecular remission has been achieved despite withdrawal of tyrosine kinase inhibitor (TKI) therapy.
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, No. 1 A'Beckett Street, Melbourne, Victoria 8006, Australia. david.ritchie@petermac.org